ValuEngine upgraded shares of Protagenic Therapeutics (OTCMKTS:PTIX) from a hold rating to a buy rating in a report published on Tuesday morning, ValuEngine reports.

Shares of Protagenic Therapeutics stock opened at $1.50 on Tuesday. Protagenic Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $2.50. The business’s fifty day simple moving average is $1.50.

Protagenic Therapeutics (OTCMKTS:PTIX) last issued its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.06) earnings per share for the quarter.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder.

Featured Story: Why do corrections happen?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.